



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/50, 9/16, 31/495		A1	(11) International Publication Number: WO 98/00116
			(43) International Publication Date: 8 January 1998 (08.01.98)
<p>(21) International Application Number: PCT US97 10122</p> <p>(22) International Filing Date: 25 June 1997 (25.06.97)</p> <p>(30) Priority Data: 08/672,432 28 June 1996 (28.06.96) US</p> <p>(71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).</p> <p>(72) Inventors: SANGEKAR, Surendra, A.; 127 Sinclair Avenue, Union, NJ 07083 (US). VADINO, Winston, A.; 9 Glenmont Road, Whitehouse Station, NJ 08889 (US). LEE, Ping, I.; 312 Pine Tree Road, Radnor, PA 19087 (US).</p> <p>(74) Agents: MAJKA, Joseph, T. et al., Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).</p>			
<p>(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p>			
<p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> </p>			

(54) Title: ORAL COMPOSITION COMPRISING A TRIAZOLE ANTIFUNGAL COMPOUND

(57) Abstract

A pharmaceutical composition comprising: i) substantially inert beads, wherein said beads are coated with ii) an antifungal agent which is (2R-cis)-4-[4-[4-[5-(2,4-difluorophenyl)-tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-[(S)-1-ethyl-2(S)-hydroxypropyl]-3H-1,2,4-triazol-3-one; iii) a binder to enable the antifungal compound to adhere to said beads. The composition enables the antifungal compound, which has very low water solubility, to have enhanced bioavailability in mammals, such as humans.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ORAL COMPOSITION COMPRISING A TRIAZOLE ANTIFUNGAL COMPOUND

5

BACKGROUND OF THE INVENTION


The present invention relates to compositions having enhanced or improved bioavailability for a novel triazole antifungal compound.

International Patent Publication Number WO 95/17407 published 29 June 10 1995, teaches a novel class of tetrahydrofuran/triazole antifungal compounds. One particular compound, (2R-cis)-4-[4-[4-[4-[[5-(2,4-difluorophenyl)-tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl]phenyl]2-4-dihydro-2-[(S)-1-ethyl-2(S)-hydroxypropyl]-3H-1,2,4-Triazol-3-One ("the antifungal compound"), was found to have potent antifungal 15 activity in suspensions against opportunistic fungi such as Aspergillus, Candida, Cryptococcus and other opportunistic fungi. However, solid compositions, such as powders or granules, were found to have reduced anti-fungal activity and/or bioavailability, presumably due to this compound's extremely low water solubility. It would be desirable to provide this antifungal compound in a 20 pharmaceutical composition whose antifungal and/or bioavailability would be enhanced or improved.

SUMMARY OF THE INVENTION

The present invention is directed to a pharmaceutical composition comprising:

- i) a plurality of beads; wherein said beads are coated with
- ii) an antifungal agent of the formula:



and


The pharmaceutical composition may also contain other excipients such as iv) surfactants, v) plasticizers, vi) defoaming agents and coloring agents. The pharmaceutical composition can also be formulated into any other suitable delivery system or dosage form, such as capsules, tablets, or beads for reconstitution.

It has also been surprisingly and unexpectedly found that the coating of beads with the antifungal compound using a suitable binder, can enhance or be equivalent to the bioavailability of the antifungal compound compared to suspensions. These results are truly surprising and unexpected, since known references, such as Peter G. Welling, Pharmacokinetics, Processes and Mathematics, American Chemical Society, Washington DC, ACS Monograph 185, 1986, page 57, teaches that solutions and suspensions generally give rise to more satisfactory bioavailability than capsules or tablets. J.G. Nairn, Remington's Pharmaceutical Sciences, 18th Edition, 1990, Mack Publishing Co., Chapter 83, page 1519 also teaches that since drugs are absorbed in their dissolved state, frequently it is found that the absorption rate of oral dosage forms decreases in the following order: aqueous solution>aqueous suspension>capsule or tablet.

The present invention has the advantage of being able to provide the antifungal compound in a pharmaceutical composition that can conveniently be formulated into solid or "dry" delivery systems or dosage forms such as capsules, tablets or loose beads having effective antifungal activity and/or bioavailability.


25 **DETAILED DESCRIPTION OF THE EMBODIMENTS**

WO 95/17407 published 29 June 1995 discloses antifungal compounds of the formula:



wherein R¹ is a straight or branch chain (C3 to C8) alkyl group substituted by one or two hydroxy moieties; esters and ethers thereof or a pharmaceutically

acceptable salt thereof. An especially preferred compound of the above group taught in Examples 24 and 32 of WO 95/17407 is the antifungal compound, (−)-
 (2R-cis)-4-[4-[4-[5-(2,4-difluorophenyl)-tetrahydro-5-(1H-1,2,4-triazol-1-
 ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-[(S)-1-
 5 ethyl-2(S)-hydroxypropyl]-3H-1,2,4-triazol-3-one ("the antifungal compound");
 Formula: C₃₇H₄₂F₂N₈O₄; Molecular weight: 700.8; m.p. 164-165 C, [a]_D²⁵
 -29°C ± 3° (c = 1.0, CHCl₃), whose structure is depicted below:



10 Micron-sized particles of the antifungal compound can be obtained either
 by the final step during the manufacture of the antifungal compound or by the
 use of conventional micronizing techniques after the conventional crystallization
 procedure(s).

15 Where micronizing techniques are employed, the antifungal compound
 may be micronized to the desired particle size range by conventional
 techniques, for example, using a ball mill, ultrasonic means, or preferably using
 fluid energy attrition mills such as the trost fluid energy mill from Plastomer
 Products, Newton, Pennsylvania 18940. When using a fluid energy attrition
 mill, the desired particle size can be obtained by varying the feed rate of the
 antifungal into the mill.

20 About 99% of the of the micronized antifungal particle are less than or
 equal to 100 microns in length, of which 95% are less than or equal to 90
 microns. Preferably, about 99% of the micronized particles are less than or
 equal to 50 microns, of which 95% are less than or equal to 40 microns. More
 preferably, 99% of the micronized particles are less than or equal to 20 microns,
 25 of which 95% are less than or equal to 10 microns.

The antifungal compound is employed in the composition in amounts

100000 to about 10000000 milligrams per liter of the composition, typically
 6° to about 40°, most preferably from about 5 to about 33° by weight. The

amount of composition in the particular dosage form, e.g. capsule, tablet, etc., can range from about 10 to about 300 mg antifungal compound per dosage form, preferably from about 50 to about 200 mg.

Compositions of the present invention can be prepared by dissolving or 5 suspending the antifungal compound in an a suitable solvent system containing a binder, and optionally with one or more ingredients such as a surfactant, plasticizer, defoaming agent and/or coloring agent and coating the solution or suspension on the inert beads.

The pharmaceutical composition of the present invention can be 10 formulated into any suitable dosage form, such as capsules, tablets or loose beads for constitution. For example, the above composition can be compressed into tablet form using a suitable cushioning agent, such as microcrystalline cellulose, and optionally, a disintegrant, lubricant, glidant, and the like.

The following terms are used to describe the present pharmaceutical 15 compositions, ingredients which can be employed in its formulation and methods for assessing its bioactivity or bioavailability.

The beads or seeds are discrete particles, preferably spherical particles or spheres, which serve as the solid substrate upon which the antifungal compound is coated, and make up the major portion of the composition or 20 dosage form. Beads can be made of sugars such as lactose, sucrose, mannitol and sorbitol; other beads can be derived from starches derived from wheat, corn rice and potato; and celluloses such as microcrystalline cellulose. A source of sugar beads (non-pareil seeds) is known as Nu-pareil PG, tradename of Crompton and Knowles Ingredient Technology Corporation, of Mahawah, New 25 Jersey. A source of microcrystalline cellulose beads is known as Celphere, tradename of the FMC Corporation, Philadelphia, Pennsylvania. Beads of differing mesh sizes can be employed, such as 18/20 mesh, 25/30 mesh and 40/50 mesh. Such mesh sizes refer to particle or bead sizes whose diameters can ranges from about 1.0 millimeters (mm) to about 0.297 mm. Preferably the 30 bead sizes or diameters are within a relative narrow range such as, for example, between about 1.0-0.84 mm (18/20 mesh), or between about 0.71-0.59 mm (25/30 mesh), or between about 0.42-0.297 mm (40/50 mesh). The beads should be "inert" meaning that the beads themselves have little or no antifungal effectiveness. The amount of beads in the composition can range

from about 50 to about 90% by weight of the total composition, preferably from about 60 to about 80%, more preferably from about 65 to about 75% by weight.

Binders - refers to substances that bind or "glue" the antifungal compound and other ingredients onto the beads, enabling the beads to be 5 coated. Suitable binders include sugars such as sucrose; starches derived from wheat, corn rice and potato; natural gums such as acacia, gelatin and tragacanth; derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate; cellulosic materials such as methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose 10 and sodium carboxymethylcellulose; polyvinylpyrrolidone (Povidones); protein hydrolysates; methacrylic acid and salts thereof; and inorganic compounds such as magnesium aluminum silicate. A commercially available formulation useful as a binder is known as Opadry powders, tradename of the Coloron Corporation, West Point, Pennsylvania. Opadry powders may contain 15 hydroxypropylmethylcellulose, along with a plasticizer such as polyethylene glycol and a surfactant such as polysorbate-80. The amount of binder in the composition can range from about 1 to about 10% by weight of the composition, preferably from about 2 to about 8% by weight, more preferably from about 3 to about 6%.


20 Disintegrants - refers to materials added to the composition to help it break apart (disintegrate) and release the medicaments. Suitable disintegrants include starches; "cold water soluble" modified starches such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar; cellulose derivatives such as methylcellulose and 25 sodium carboxymethylcellulose; microcrystalline celluloses and cross-linked microcrystalline celluloses such as sodium croscarmellose; alginates such as alginic acid and sodium alginate; clays such as bentonites; and effervescent mixtures. The amount of disintegrant in the composition can range from about 2 to about 15% by weight of the composition, more preferably from about 4 to 30 about 10% by weight.

Surfactant - refers to a compound that can reduce the interfacial tension between two immiscible phases and this is due to the molecule containing two localized regions, one being hydrophilic in nature and the other hydrophobic

35 and do not dissociate to an appreciable extent in aqueous media. The

properties of non-ionic surfactants are largely dependent upon the proportions of the hydrophilic and hydrophobic groups in the molecule. Hydrophilic groups include the oxyethylene group (-OCH₂CH₂-) and the hydroxy group. By varying the number of these groups in a hydrophobic molecule, such as a fatty acid, 5 substances are obtained which range from strongly hydrophobic and water insoluble compounds, such as glyceryl monostearate, to strongly hydrophilic and water-soluble compounds, such as the macrogols. Between these two extremes, there include those in which the proportions of the hydrophilic and hydrophobic groups are more evenly balanced, such as the macrogol esters 10 and ethers and sorbitan derivatives. Suitable non-ionic surfactants may be found in Martindale, The Extra Pharmacopoeia, 28th Edition, 1982, The Pharmaceutical Press, London, Great Britain, pp. 370 to 379. Such non-ionic surfactants include block copolymers of ethylene oxide and propylene oxide, glycol and glyceryl esters of fatty acids and their derivatives, polyoxyethylene 15 esters of fatty acids (macrogol esters), polyoxyethylene ethers of fatty acids and their derivatives (macrogol ethers), polyvinyl alcohols, and sorbitan esters. Preferably, the non-ionic surfactant is a block copolymer of ethylene oxide and propylene oxide.

Suitable block copolymers of ethylene oxide and propylene oxide 20 generically called "Poloxamers" and include those represented by the following chemical structure:



wherein a is an integer ranging from about 10 to about 110, preferably from 25 about 12 to 101; more preferably from about 12 to 80; and b is an integer ranging from about 20 to about 60, more preferably from about 20 to about 56; also from about 20 to 27. Most preferably, a is 80 and b is 27, otherwise known as Pluronic®F68 surfactant, trademark of the BASF Corporation, Mount Olive, New Jersey, USA. Pluronic®F68 surfactant is also known as Poloxamer 188. This surfactant has an average molecular weight of 30 8400, is a solid at 20°C, has a viscosity (Brookfield) of 1000 cps at 77°C. Other suitable block copolymers of ethylene oxide and propylene oxide include Pluronic F87, also known as Poloxamer 237 wherein a is 64 and b is 37; and Pluronic F127, also known as Poloxamer 407 wherein a is 101 and b is 56.

Suitable glycol and glyceryl esters of fatty acids and their derivatives 35 include glyceryl monooleate and similar water soluble derivatives;

Suitable polyoxyethylene esters of fatty acids (macrogol esters) include polyoxyethylene castor oil and hydrogenated castor oil derivatives;

Suitable polyoxyethylene ethers of fatty acids and their derivatives (macrogol ethers) include Cetomacrogel 1000, Lauromacrogols (a series of

- 5 lauryl ethers of macrogols of differing chain lengths) e.g. Laureth 4, Laureth 9 and Lauromacrogol 400.

Suitable Sorbitan esters (esters of one or more of the hydroxyl groups in the sorbitans, with a fatty acid, such as stearic, palmitic, oleic or lauric acid) include, e.g. Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 65,

- 10 Polysorbate 80, Polysorbate 85, Sorbitan Monolaurate, Sorbitan Mono-oleate, Sorbitan Monopalmitate, Sorbitan Monostearate, Sorbitan Sesquioleate, Sorbitan Trioleate and Sorbitan Tristearate.

The amount of surfactant in the composition can range from about 0.5 to about 25% by weight of the total composition, more preferably from about 5 to

- 15 about 15% by weight.

Anionic surfactant - refers to a surfactant which has a net negative ionic charge and dissociates to an appreciable extent in aqueous media. Optionally,

the present composition may also contain an anionic surfactant, e.g. sodium lauryl sulfate, the amount of which can range from about 1 to about 10% by

- 20 weight of the total composition, more preferably from about 3 to about 8% by weight.

Plasticizers-refers to substances which make the binder flexible.

Suitable plasticizers include propylene glycol, glycerin, diethylphthalate, dibutyl sebacate, triethyl citrate, hydrogenated glycerides, polyethylene glycols,

- 25 polyethylene oxides, triacetin and the like. The amount of plasticizer in the composition can be in the range of about 1-2 to about 5% by weight.

Defoaming agents, also known as antifoaming agents, are substances used to reduce foaming due to mechanical agitation or to gases, nitrogenous

materials or other substances which may interfere during processing. Examples include metallic salts such as sodium chloride; C6 to C12 alcohols such as

octanol; sulfonated oils; silicone ethers such as simethicone; organic

phosphates and the like. The amount of defoaming agent in the composition can range from about 0.05 to 5% preferably from about 0.1 to 2%.

characteristics of granulations, so that flow is smooth and uniform. Suitable

glidents include silicon dioxide and talc. The amount of glidient in the composition can range from about 0.1% to about 5% by weight of the total composition, preferably from about 0.5 to about 2% by weight.

5 Lubricant - refers to a substance added to the dosage form to enable the tablet, granules, etc. after it has been compressed, to release from the mold or die by reducing friction or wear. Suitable lubricants include metallic stearates such as magnesium, calcium or potassium stearate; stearic acid; high melting point waxes; and water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and d'l-leucine.

10 Lubricants are usually added at the very last step before compression, since they must be present on the surfaces of the granules and in between them and the parts of the tablet press. The amount of lubricant in the composition can range from about 0.2 to about 5% by weight of the composition, preferably from about 0.5 to about 2%.

15

Coloring agents - excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes and food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide. The amount of the coloring agent can vary from about 0.1 to about 5% by weight of the composition, preferably from about 0.1 to about 1%.

20

25 Dosage form - composition containing the antifungal compound formulated into a delivery system, i.e., tablet, capsule, oral gel, powder for constitution or suspension in association with inactive ingredients.

25

Capsule - refers to a special container or enclosure made of methyl cellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active antifungal compound. Hard shell capsules are typically made of blends of relatively high gel strength bone and pork skin gelatins. The capsule itself may contain small amounts of dyes, opaquing agents, plasticizers and preservatives.

30

35 Tablet- refers to a compressed or molded solid dosage form containing the active ingredient (antifungal compound) with suitable diluents. The tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation, compaction or compression of mixtures containing coated active beads.

Beads for constitution refers to the loose, coated beads which can be suspended in water, juices or sauces such as applesauce.

5 Bioavailability - refers to the rate and extent to which the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control.

10 C_{max} values refers to the maximum concentration of the antifungal compound measured (i.e. "peak") in the plasma serum.

15 AUC (0-72 hr) values refer to the area under the plasma/serum concentration-time curve for the antifungal over a designated time.

20 Conventional methods for preparing tablets are known. Such methods include dry methods such as direct compression and compression of granulation produced by compaction, or wet methods or other special procedures.

25 The following examples describe compositions of the present invention containing the antifungal compound, but they are not to be interpreted as limiting the scope of the claims.

Example 1. Coated Beads in Capsules

<u>Ingredient</u>	<u>g/batch</u>	<u>% wt basis</u>
Antifungal compound, micronized	135	20.3
Opadry YS-1-7006	30	4.5
Simethicone	1.42	0.2
Water purified, USP (evaporates)	700 mL	-
Non-Pareil Seeds (25/30 mesh)	<u>500</u>	<u>75</u>
	666.42	100%

Example 2. Coated Beads in Capsules

<u>Ingredient</u>	<u>mg/batch</u>	<u>% wt basis</u>
Antifungal compound, micronized	75	11.0
Opadry YS-1-7006	30	4.4
Pluronic F68 surfactant	75	11.0
Simethicone	0.7	0.1
Water purified, USP (evaporates)	500 mL	-
Non-Pareil Seeds (25/30 mesh)	<u>500</u>	<u>73.5</u>
	680.7	100%

5

Preparation of Coated Beads in Capsules in Examples 1, 2 and 5

Dissolve the Opadry YS-1-7006, Pluronic F68 or sodium lauryl sulfate in water.

Add simethicone while stirring. Add the antifungal compound while stirring slowly until a homogeneous suspension is formed. Screen the suspension

10 through a 25 mesh hand screen. Spray the suspension onto the non-pareil seeds using a fluid bed coater. Dry the coated beads overnight and assay the coated beads to determine the amount of antifungal compound. Fill the coated beads into suitable size capsules to the requisite fill weight.

15

Preparation of Aqueous Suspension in Comparative Example 3

Prepare a suspension containing 59.8 mg Pluronic F68 in four mL of distilled water. Add 200 mg of antifungal compound to the above solution and mix to

5 give a homogeneous suspension.

Preparation of Powder Mixture in Capsules in Comparative Example 4

<u>Ingredient</u>	<u>mg/capsule</u>	<u>% wt basis</u>
-------------------	-------------------	-------------------

Antifungal compound, micronized	100.0	28.6
Sodium lauryl sulfate surfactant	22.5	6.4
Microcrystalline cellulose	178.0	50.9
Sodium starch glycolate	45.0	12.8
Magnesium stearate	<u>4.5</u>	<u>1.3</u>
	350	100

Mix the antifungal compound, sodium lauryl sulfate (a surfactant),

10 microcrystalline cellulose, and sodium starch glycolate in a blender for 10 minutes. Add magnesium stearate and mix for 5 minutes to form a homogeneous powder. Fill the powder into suitable size capsules to the requisite fill weight.

15

Testing for Bioavailability

Dogs are administered a 200 mg dose of the antifungal compound using two capsules or in suspension. Samples of serum are collected at selected times and analyzed by an HPLC/UV detection procedure using a high pressure liquid chromatograph equipped with an ultra-violet detector. In the table below, the C_{max} and AUC (0-72 hr) values are indicators of the antifungal compound's bioavailability. The larger the AUC value, the greater the total amount of antifungal compound that accumulated in the plasma serum over the 72 hour period.

<u>Indicator of Bioavailability</u>	Coated Beads in Capsules- Example 1	Coated Beads in Capsules- Example 2	Control Suspension- Comparative Example 3	Powder Mixture in Capsules- Comparative Example 4
C_{max} (ug/ml)	1.43	1.37	1.21	0.95
AUC(0-72 hr) ug/hr/ml	50.21	50.17	47.98	29.72

The results above show that capsules of Examples 1 and 2 exhibit enhanced bioavailability over that of the aqueous suspension of Comparative Example 3 and 5 especially over the powdered mixture in capsules of Comparative Example 4.


Example 5. Coated Beads in Capsules

<u>Ingredient</u>	<u>g/batch</u>	<u>% wt basis</u>
Antifungal compound, micronized	75.0	11.80
Opadry YS-1-7006	30.0	4.72
Sodium lauryl sulfate	30.0	4.72
Simethicone	1.0	0.16
Water purified, USP (evaporates)	500 mL	-
Non-Pareil Seeds (25/30 mesh)	500.0	78.60
	636.0	100%

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising:

 - i) a plurality of beads; wherein said beads are coated with
 - ii) an antifungal agent of the formula:



5 and

2. The composition of claim 1 wherein the beads are made of sugar, starch or microcrystalline cellulose.

10

3. The composition of claim 1 wherein the beads are made of sugar.

4. The composition of claim 1 wherein the beads have a mesh size ranging between about 18/20 to 45/50.

15

5. The composition of claim 1 wherein the amount of antifungal compound in the composition can range from about 5 to about 33% by weight.

6. The composition of claim 1 wherein the binder is

20 hydroxypropylmethylcellulose.

7. The composition of claim 1 further comprising

iv) a surfactant.

25 8. The composition of claim 7 wherein the surfactant is a non-ionic surfactant.

9 The composition of claim 7 wherein the surfactant is a block copolymer of

10. The composition of claim 7 wherein the surfactant is an anionic surfactant.
11. The composition of claim 10 wherein the anionic surfactant is sodium lauryl sulfate.
12. The composition of claim 7 further comprising v) a plasticizer.
- 10 13. The composition of claim 12 wherein the plasticizer is polyethylene glycol.
14. The composition of claim 13 further comprising vi) a defoaming agent.
- 15 15. The composition of claim 14 wherein the defoaming agent is simethicone.
16. The composition of claim 1 in the dosage form of a capsule.
- 20 17. The composition of claim 16 wherein the amount of antifungal compound in the capsule is in the range of about 50 to 300 milligrams.
- 25 18. The composition of claim 16 wherein the amount of antifungal compound in the capsule is in the range of about 50 to 200 milligrams.
19. The pharmaceutical composition of claim 1 further comprising about 11-20% by weight of the antifungal compound; about 73-75% by weight beads;
- 30 about 0.5-15% by weight of a surfactant; about 4.7-5% by weight of a binder which is hydroxypropylmethyl cellulose; and about 0.5-1.5% by weight of a defoaming agent.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/10122

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 9/50, A61K 9/16, A61K 31/495

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K, A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAPLUS, WPI, USPATFULL, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	WO 9405263 A1 (JANSSEN PHARMACEUTICA N.V.), 17 March 1994 (17.03.94), page 2, line 23 - page 3, line 13; page 3, line 24 - line 35 --	1-19
A	WO 9517407 A1 (SCHERING CORPORATION), 29 June 1995 (29.06.95) --	1-19
A	EP 0636366 A2 (EUROCELTIQUE S.A.), 1. February 1995 (01.02.95) -----	1-19

 Further documents are listed in the continuation of Box C See patent family annex

- * Special categories of cited documents
- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel, or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

28 October 1997

Name and mailing address of the ISA
 European Patent Office, 3, B-1049 Luxembourg
 11, rue F. D. Roosevelt
 L-1049 Luxembourg
 Tel. (02) 46 41 00 00

Authorized officer

Annelies De Bruyn

11.11.97

INTERNATIONAL SEARCH REPORT

ISA 154718

Information on patent family members

01/10/97

International application No.
PCT/US 97/10122

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9405263 A1	17/03/94	AP 444 A AP 9300563 D AT 145327 T AU 665867 B AU 4954693 A CA 2142848 A CN 1088432 A CZ 9500542 A DE 69306119 D, T EP 0658103 A, B ES 2097536 T FI 950975 A HR 931158 A HU 70419 A HU 9500642 D JP 8501092 T MX 9305438 A NO 950829 A NZ 255379 A PL 307791 A SI 9300461 A US 5633015 A ZA 9306493 A	19/01/96 00/00/00 15/12/96 18/01/96 29/03/94 17/03/94 29/06/94 13/09/95 13/03/97 21/06/95 01/04/97 02/03/95 30/06/95 30/10/95 00/00/00 06/02/96 31/03/94 02/05/95 25/06/96 26/06/95 31/03/94 27/05/97 02/03/95
WO 9517407 A1	29/06/95	AU 681753 B AU 1512795 A CA 2179396 A CN 1142828 A CZ 9601805 A EP 0736030 A FI 962577 A HU 75879 A HU 9601709 D IL 112081 D JP 9500658 T NO 962616 A PL 315169 A SK 82696 A US 5661151 A ZA 9410142 A	04/01/97 10/06/95 29/06/95 12/02/97 15/01/97 09/10/96 20/06/96 28/05/97 00/00/00 00/00/00 21/01/97 07/08/96 14/10/96 05/03/97 26/08/97 02/05/96
EP 0636366 A2	01/02/95	AU 6868994 A CA 2128591 A US 5580578 A US 5639476 A	09/02/95 28/01/95 03/12/96 17/06/97